Carbylan Therapeutics Inc Share Price Nasdaq
Equities
US1413841073
Pharmaceuticals
Sales 2024 * | - | Sales 2025 * | 14.95M 1.24B | Capitalization | 503M 41.87B |
---|---|---|---|---|---|
Net income 2024 * | -114M -9.49B | Net income 2025 * | -111M -9.24B | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M 18.18B | Net cash position 2025 * | 105M 8.72B | EV / Sales 2025 * | 26.6 x |
P/E ratio 2024 * |
-3.92
x | P/E ratio 2025 * |
-4.94
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.86% |
Latest transcript on Carbylan Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 26/04/26 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01/16/01 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 03/21/03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 01/19/01 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01/16/01 |
Albert Cha
BRD | Director/Board Member | 51 | 01/16/01 |
1st Jan change | Capi. | |
---|---|---|
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B | |
-6.32% | 8.35B |